Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data shows lanadelumab cuts HAE attacks over three years

NCT ID NCT04130191

Completed Disease control Sponsor: Shire Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study followed 140 people with hereditary angioedema (HAE) who were already taking lanadelumab. Researchers compared the number of swelling attacks during treatment to the number before starting the drug. Participants reported their symptoms via a smartphone app and during clinic visits for up to three years. The goal was to see how well lanadelumab works in everyday life, not just in controlled trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lanadelumab
What this could lead to
If successful, this study could confirm that lanadelumab effectively reduces HAE attacks in everyday use, supporting its long-term role in managing the condition.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection or reporting bias. It does not test new treatments or cures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY ANGIOEDEMA (HAE)

Contacts and locations

Locations

  • ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco

    Milan, 20157, Italy

  • Al-Rashed Allergy Center

    Kuwait City, 90806, Kuwait

  • Azienda Ospedale Università Padova

    Padova, 35128, Italy

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Campania, 80131, Italy

  • Bnai Zion Medical Center

    Haifa, 31048, Israel

  • Charité - Universitätsmedizin Berlin

    Berlin, 10117, Germany

  • Hospital Universitario Vall d'Hebron - PPDS

    Barcelona, 08035, Spain

  • Hospital Universitario de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Hämophilie Zentrum Rhein Main GmbH

    Mörfelden-Walldorf, 64546, Germany

  • Klinikum der Johann-Wolfgang Goethe-Universitat

    Frankfurt am Main, Hesse, 60590, Germany

  • Klinikum rechts der Isar der Technischen Universität München

    München, 81675, Germany

  • Luzerner Kantonsspital LUKS

    Lucerne, 6000, Switzerland

  • Medical University of Vienna

    Vienna, 1090, Austria

  • Sheba Medical Center - PPDS

    Ramat Gan, 52621, Israel

  • Universitatsklinikum Dusseldorf

    Düsseldorf, 40225, Germany

  • Universitatsklinikum Schleswig-Holstein

    Lübeck, 23538, Germany

  • Universitätsklinikum Münster

    Münster, 48149, Germany

  • Universitätsklinikum Ulm

    Ulm, 89075, Germany

  • Universitätsspital Basel

    Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.